[ad_1]
CEO Sergio Marullo di Condojanni believes that in the coming years the Angelini Industries group will be even bigger and more international than it is now, entering “the American pharmaceutical and healthcare markets where we need to be”. The entry angle could be rare diseases “, he explains, leaving behind a record budget. Proudly. Those who “have their heads, hearts and taxes in Italy”, he says.
Professor Marullo di Condojanni, how has the last year been like for you?
In 2023, the Group achieved its highest revenue ever: more than €2.1 billion, 7.6% more than in 2022. The increase in turnover was accompanied by an increase in the total operating margin, which reached €303.7 million, up 19.2% in a year, and a 22.8% increase in net profit to €98.3 million. The increase in margin was greater than the increase in revenue. However, for us, this is the beginning of a path where we can see further development both organically and through acquisitions at home and abroad.
What is your attitude towards shareholder ownership?
We want to maintain control of the company, we have strong solvency and financial soundness, but we are open to the entry of minority shareholders: in the case of strategic operations aimed at growth, we can evaluate different structures.
[ad_2]
Source link
